Code No.  Generic Name Classification Target Disease Phase 1 Phase 2 Phase 3 Filed Area Dosage  Form Origin Remarks Oncology MDV3100 enzalutamide Androgen receptor  inhibitor Metastatic castration-resistant  prostate cancer in patients  who have not received  chemotherapy US Oral Medivation New  indication (14/03) Europe (14/04) Japan Asia Non-metastatic castration- resistant prostate cancer US New  indication Europe Asia Breast cancer US/ Europe New  indication erlotinib HER1/EGFR tyro- sine kinase inhibitor Pediatric ependymoma US Oral In-house  (co-  development  with Roche/  Genentech) Not a new  indication, rather  a supplement  whose results  are to be  submitted to  the FDA ASP3550 degarelix GnRH antagonist Prostate cancer (Three-month formulation) Japan Injection Ferring New  formulation* 1 AMG 102 rilotumumab Anti-HGF monoclonal  antibody Gastric cancer Japan Injection Amgen (co- development  with Amgen  Astellas) * 1 ASP1707 GnRH antagonist Prostate cancer Europe Oral In-house AGS-16M8F/ AGS-16C3F Cancer (ADC technology) Injection In-house  (ADC  technology  in-licensed  from Seattle  Genetics) ASG-22ME Cancer (ADC technology) Injection In-house  (co- development  with Seattle  Genetics) ASG-15ME Cancer (ADC technology) Injection In-house  (co- development  with Seattle  Genetics) ASP2215 Cancer Oral In-house ASP5878 Cancer Oral In-house AMG 337 Gastric cancer Oral Amgen (co- development  with Amgen  Astellas) * 1 ASP8273 Cancer Oral In-house AGS67E Cancer (ADC technology) Injection In-house (ADC technol- ogy in-licensed  from Seattle  Genetics) Products currently under clinical development (continued)  (as of August 1, 2014) *1 Local development (Japan) Annual Report 2014 _  Astellas Pharma Inc.  39 Review of Operations